| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 134 | 2024 | 1894 | 13.040 |
Why?
|
| Carcinoma, Papillary | 29 | 2018 | 566 | 3.600 |
Why?
|
| Adenocarcinoma, Follicular | 17 | 2019 | 131 | 3.260 |
Why?
|
| Iodine Radioisotopes | 36 | 2024 | 387 | 3.050 |
Why?
|
| Phenylurea Compounds | 25 | 2024 | 600 | 2.760 |
Why?
|
| Quinolines | 13 | 2024 | 402 | 2.510 |
Why?
|
| Protein Kinase Inhibitors | 34 | 2024 | 4961 | 2.290 |
Why?
|
| Proto-Oncogene Proteins c-ret | 16 | 2023 | 374 | 2.230 |
Why?
|
| Carcinoma, Neuroendocrine | 15 | 2021 | 743 | 2.160 |
Why?
|
| Thyroidectomy | 21 | 2019 | 489 | 1.790 |
Why?
|
| Antineoplastic Agents | 41 | 2024 | 14617 | 1.700 |
Why?
|
| Pyridines | 20 | 2024 | 1313 | 1.640 |
Why?
|
| Anilides | 10 | 2024 | 295 | 1.560 |
Why?
|
| Carcinoma, Medullary | 12 | 2016 | 248 | 1.360 |
Why?
|
| Carcinoma | 20 | 2019 | 2610 | 1.350 |
Why?
|
| Thyroid Gland | 16 | 2020 | 366 | 1.240 |
Why?
|
| Niacinamide | 16 | 2014 | 428 | 1.110 |
Why?
|
| Calcitonin | 6 | 2017 | 182 | 1.070 |
Why?
|
| Indoles | 12 | 2016 | 1028 | 1.030 |
Why?
|
| Molecular Targeted Therapy | 9 | 2019 | 2399 | 0.930 |
Why?
|
| Proto-Oncogene Proteins B-raf | 11 | 2019 | 1336 | 0.860 |
Why?
|
| Adenoma, Oxyphilic | 6 | 2019 | 76 | 0.840 |
Why?
|
| Thyrotropin | 11 | 2013 | 124 | 0.830 |
Why?
|
| Biomarkers, Tumor | 12 | 2019 | 10708 | 0.730 |
Why?
|
| Humans | 165 | 2024 | 270740 | 0.640 |
Why?
|
| Disease-Free Survival | 23 | 2017 | 10265 | 0.630 |
Why?
|
| Liraglutide | 1 | 2017 | 16 | 0.610 |
Why?
|
| Hypothyroidism | 6 | 2009 | 206 | 0.610 |
Why?
|
| Middle Aged | 89 | 2024 | 90352 | 0.600 |
Why?
|
| Benzenesulfonates | 8 | 2011 | 196 | 0.590 |
Why?
|
| Thyroxine | 6 | 2009 | 114 | 0.570 |
Why?
|
| Disease Progression | 12 | 2019 | 6867 | 0.570 |
Why?
|
| Hypoglycemic Agents | 3 | 2017 | 599 | 0.570 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2020 | 10400 | 0.560 |
Why?
|
| Double-Blind Method | 12 | 2021 | 2580 | 0.550 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 2024 | 361 | 0.550 |
Why?
|
| Proteinuria | 1 | 2017 | 155 | 0.530 |
Why?
|
| Male | 91 | 2024 | 128315 | 0.530 |
Why?
|
| Thyroid Epithelial Cells | 1 | 2015 | 2 | 0.530 |
Why?
|
| Diarrhea | 2 | 2017 | 716 | 0.530 |
Why?
|
| Mutation | 16 | 2021 | 15912 | 0.520 |
Why?
|
| Neoplasm Metastasis | 16 | 2021 | 5315 | 0.500 |
Why?
|
| Adenocarcinoma, Papillary | 3 | 2011 | 69 | 0.500 |
Why?
|
| Aged | 68 | 2024 | 73333 | 0.490 |
Why?
|
| Adult | 69 | 2021 | 82040 | 0.480 |
Why?
|
| Exanthema | 1 | 2017 | 212 | 0.480 |
Why?
|
| Adenocarcinoma | 7 | 2024 | 7914 | 0.470 |
Why?
|
| Thyroglobulin | 10 | 2020 | 65 | 0.460 |
Why?
|
| Female | 89 | 2024 | 148940 | 0.460 |
Why?
|
| Sulfonamides | 6 | 2019 | 1933 | 0.460 |
Why?
|
| Radiation Tolerance | 6 | 2021 | 639 | 0.450 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2013 | 231 | 0.450 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 1958 | 0.440 |
Why?
|
| Thyrotropin Alfa | 1 | 2013 | 1 | 0.430 |
Why?
|
| Lymph Node Excision | 4 | 2012 | 2062 | 0.430 |
Why?
|
| ras Proteins | 2 | 2016 | 804 | 0.420 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 637 | 0.380 |
Why?
|
| Imidazoles | 5 | 2021 | 1065 | 0.380 |
Why?
|
| Clinical Trials as Topic | 6 | 2017 | 3844 | 0.380 |
Why?
|
| Neck Dissection | 4 | 2014 | 294 | 0.380 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 557 | 0.370 |
Why?
|
| Treatment Outcome | 36 | 2021 | 33737 | 0.370 |
Why?
|
| Genetic Therapy | 1 | 2018 | 1716 | 0.370 |
Why?
|
| Parathyroid Neoplasms | 3 | 2021 | 190 | 0.370 |
Why?
|
| Survival Analysis | 16 | 2021 | 9292 | 0.360 |
Why?
|
| Cell Differentiation | 6 | 2021 | 4116 | 0.360 |
Why?
|
| Fatigue | 1 | 2017 | 1275 | 0.360 |
Why?
|
| MAP Kinase Signaling System | 3 | 2010 | 885 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2024 | 6256 | 0.340 |
Why?
|
| Registries | 7 | 2020 | 2211 | 0.340 |
Why?
|
| raf Kinases | 3 | 2011 | 80 | 0.340 |
Why?
|
| Aged, 80 and over | 34 | 2021 | 30998 | 0.330 |
Why?
|
| Autoantibodies | 4 | 2020 | 602 | 0.330 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2012 | 1838 | 0.320 |
Why?
|
| Germ-Line Mutation | 4 | 2019 | 1101 | 0.310 |
Why?
|
| Tetrahydronaphthalenes | 3 | 2006 | 114 | 0.310 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2003 | 304 | 0.300 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2008 | 127 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2014 | 2386 | 0.290 |
Why?
|
| Thyroiditis, Subacute | 1 | 2007 | 2 | 0.290 |
Why?
|
| Thyroid Crisis | 1 | 2007 | 6 | 0.290 |
Why?
|
| Prognosis | 18 | 2024 | 22505 | 0.290 |
Why?
|
| Drug Design | 1 | 2009 | 372 | 0.280 |
Why?
|
| Indazoles | 4 | 2019 | 310 | 0.280 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2021 | 291 | 0.280 |
Why?
|
| Neoplasm Staging | 14 | 2018 | 14012 | 0.280 |
Why?
|
| Immunotherapy | 2 | 2018 | 3557 | 0.280 |
Why?
|
| Thyrotoxicosis | 3 | 2007 | 22 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2019 | 16689 | 0.270 |
Why?
|
| Thyroid Nodule | 4 | 2017 | 92 | 0.270 |
Why?
|
| Quinolones | 3 | 2013 | 163 | 0.270 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 1260 | 0.260 |
Why?
|
| Hormones | 1 | 2007 | 285 | 0.260 |
Why?
|
| Oligonucleotides | 5 | 2010 | 242 | 0.260 |
Why?
|
| Retrospective Studies | 31 | 2024 | 39890 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2010 | 1710 | 0.240 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 15218 | 0.240 |
Why?
|
| Young Adult | 16 | 2019 | 22251 | 0.240 |
Why?
|
| Age Factors | 8 | 2024 | 5457 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 9042 | 0.230 |
Why?
|
| Neck | 4 | 2012 | 395 | 0.230 |
Why?
|
| Cohort Studies | 9 | 2019 | 9470 | 0.220 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 512 | 0.220 |
Why?
|
| Radiopharmaceuticals | 4 | 2019 | 1341 | 0.220 |
Why?
|
| Carcinoma, Papillary, Follicular | 2 | 2014 | 27 | 0.210 |
Why?
|
| Pyrroles | 5 | 2014 | 588 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2022 | 13414 | 0.200 |
Why?
|
| Professional Practice | 2 | 2012 | 80 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 7783 | 0.200 |
Why?
|
| Proportional Hazards Models | 4 | 2024 | 5101 | 0.200 |
Why?
|
| Incidence | 7 | 2019 | 5824 | 0.200 |
Why?
|
| Brachytherapy | 1 | 2008 | 1005 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2021 | 266 | 0.190 |
Why?
|
| Biopsy, Needle | 3 | 2017 | 1379 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2197 | 0.180 |
Why?
|
| Anticarcinogenic Agents | 1 | 2003 | 368 | 0.180 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2021 | 86 | 0.180 |
Why?
|
| Quinazolines | 4 | 2016 | 956 | 0.180 |
Why?
|
| Health Maintenance Organizations | 1 | 2000 | 27 | 0.180 |
Why?
|
| Pyrimidines | 5 | 2021 | 3669 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2019 | 6764 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2011 | 2271 | 0.180 |
Why?
|
| Patient Selection | 3 | 2020 | 2025 | 0.170 |
Why?
|
| Adrenal Gland Neoplasms | 3 | 2018 | 527 | 0.170 |
Why?
|
| Adolescent | 21 | 2022 | 32767 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 4048 | 0.170 |
Why?
|
| SEER Program | 3 | 2014 | 1047 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 485 | 0.170 |
Why?
|
| Blood Glucose | 1 | 2024 | 1269 | 0.170 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 89 | 0.170 |
Why?
|
| Leukocyte Count | 1 | 2021 | 735 | 0.170 |
Why?
|
| Pheochromocytoma | 2 | 2018 | 310 | 0.170 |
Why?
|
| Water | 1 | 2021 | 386 | 0.160 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 12033 | 0.160 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 5149 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2017 | 1412 | 0.160 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2018 | 35 | 0.160 |
Why?
|
| United States | 12 | 2019 | 15861 | 0.160 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2018 | 81 | 0.160 |
Why?
|
| Fibroblast Growth Factors | 2 | 2017 | 257 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 255 | 0.150 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 2357 | 0.150 |
Why?
|
| Risk Factors | 8 | 2019 | 17888 | 0.150 |
Why?
|
| Everolimus | 3 | 2016 | 436 | 0.150 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1999 | 367 | 0.150 |
Why?
|
| Hypoparathyroidism | 3 | 2011 | 49 | 0.150 |
Why?
|
| Hyperplasia | 2 | 2017 | 564 | 0.140 |
Why?
|
| Thiazolidinediones | 1 | 2018 | 147 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 5408 | 0.140 |
Why?
|
| Angiopoietin-2 | 1 | 2017 | 36 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 3476 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2024 | 1580 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 334 | 0.140 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2018 | 277 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2021 | 517 | 0.140 |
Why?
|
| Paraganglioma | 2 | 2018 | 200 | 0.140 |
Why?
|
| General Surgery | 1 | 2000 | 333 | 0.140 |
Why?
|
| Salvage Therapy | 2 | 2016 | 2123 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2002 | 1267 | 0.140 |
Why?
|
| Neutrophils | 1 | 2021 | 873 | 0.140 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 153 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2018 | 368 | 0.130 |
Why?
|
| Neoplasms | 3 | 2017 | 15927 | 0.130 |
Why?
|
| Piperidines | 3 | 2016 | 1100 | 0.130 |
Why?
|
| Sex Factors | 3 | 2024 | 2184 | 0.130 |
Why?
|
| Physician's Role | 1 | 2018 | 230 | 0.130 |
Why?
|
| Aluminum Silicates | 1 | 2015 | 16 | 0.130 |
Why?
|
| Research Design | 3 | 2017 | 1569 | 0.130 |
Why?
|
| Antidiarrheals | 1 | 2015 | 36 | 0.130 |
Why?
|
| Lymphatic Metastasis | 5 | 2016 | 4963 | 0.130 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2010 | 617 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 4960 | 0.120 |
Why?
|
| Spinal Fractures | 1 | 2016 | 138 | 0.120 |
Why?
|
| Spinal Cord Compression | 1 | 2016 | 167 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 5056 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.120 |
Why?
|
| Radionuclide Imaging | 3 | 2013 | 655 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2024 | 2232 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 339 | 0.120 |
Why?
|
| Sucralfate | 1 | 1994 | 10 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 418 | 0.120 |
Why?
|
| Retreatment | 1 | 2015 | 448 | 0.120 |
Why?
|
| Malabsorption Syndromes | 1 | 1994 | 44 | 0.120 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2011 | 73 | 0.110 |
Why?
|
| Combined Modality Therapy | 8 | 2012 | 9039 | 0.110 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 657 | 0.110 |
Why?
|
| Antithyroid Agents | 2 | 2006 | 7 | 0.110 |
Why?
|
| Pituitary Neoplasms | 2 | 2009 | 216 | 0.110 |
Why?
|
| Genetic Testing | 2 | 2023 | 1696 | 0.110 |
Why?
|
| Skin Neoplasms | 3 | 2008 | 4895 | 0.110 |
Why?
|
| Pemetrexed | 2 | 2011 | 100 | 0.110 |
Why?
|
| Neoplasm Proteins | 3 | 2013 | 3345 | 0.110 |
Why?
|
| Oximes | 1 | 2015 | 191 | 0.110 |
Why?
|
| Glutamates | 2 | 2011 | 134 | 0.110 |
Why?
|
| Age of Onset | 1 | 2015 | 853 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 3530 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 1402 | 0.110 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2003 | 125 | 0.110 |
Why?
|
| Guanine | 2 | 2011 | 157 | 0.110 |
Why?
|
| Farnesyltranstransferase | 2 | 2011 | 125 | 0.110 |
Why?
|
| Endocrinology | 1 | 2016 | 154 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2014 | 1608 | 0.110 |
Why?
|
| Tumor Burden | 2 | 2022 | 2033 | 0.100 |
Why?
|
| Parathyroid Glands | 2 | 2003 | 127 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 797 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2017 | 2422 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Drug Resistance, Multiple | 1 | 2013 | 221 | 0.100 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 1992 | 11 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2018 | 1149 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Survival Rate | 7 | 2018 | 12541 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 2650 | 0.100 |
Why?
|
| Valproic Acid | 1 | 2013 | 272 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 839 | 0.100 |
Why?
|
| Apoptosis | 3 | 2021 | 7757 | 0.100 |
Why?
|
| Growth Hormone | 1 | 1992 | 222 | 0.100 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2011 | 26 | 0.090 |
Why?
|
| Glycyrrhetinic Acid | 1 | 2011 | 7 | 0.090 |
Why?
|
| Octreotide | 1 | 1992 | 131 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 2665 | 0.090 |
Why?
|
| Biomarkers | 3 | 2023 | 5051 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2353 | 0.090 |
Why?
|
| Vocal Cord Paralysis | 1 | 2011 | 95 | 0.090 |
Why?
|
| Time Factors | 3 | 2014 | 13006 | 0.090 |
Why?
|
| Observation | 1 | 2010 | 52 | 0.090 |
Why?
|
| Radiotherapy Dosage | 5 | 2010 | 4019 | 0.090 |
Why?
|
| Incretins | 1 | 2010 | 28 | 0.090 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1991 | 211 | 0.080 |
Why?
|
| Risk | 3 | 2014 | 1939 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2009 | 484 | 0.080 |
Why?
|
| Diabetes Insipidus | 1 | 2009 | 24 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1998 | 1302 | 0.080 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2007 | 121 | 0.080 |
Why?
|
| Hypopituitarism | 1 | 2009 | 28 | 0.080 |
Why?
|
| Radiation Injuries | 2 | 2009 | 1471 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2012 | 689 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 500 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1312 | 0.080 |
Why?
|
| Child | 12 | 2021 | 30559 | 0.080 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 907 | 0.080 |
Why?
|
| Ultrasonography | 4 | 2012 | 1933 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1591 | 0.080 |
Why?
|
| Preoperative Care | 3 | 2011 | 1567 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 4831 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2009 | 130 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2010 | 2178 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 152 | 0.080 |
Why?
|
| Postoperative Care | 2 | 2010 | 728 | 0.080 |
Why?
|
| Multiple Endocrine Neoplasia | 2 | 2005 | 60 | 0.080 |
Why?
|
| Etoposide | 1 | 2010 | 907 | 0.070 |
Why?
|
| Texas | 2 | 2024 | 6449 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 613 | 0.070 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 157 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2016 | 1465 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14849 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2003 | 5681 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 4644 | 0.070 |
Why?
|
| Coronary Disease | 1 | 1991 | 766 | 0.070 |
Why?
|
| Sirolimus | 1 | 2011 | 831 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2009 | 622 | 0.070 |
Why?
|
| Genotype | 4 | 2008 | 4252 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2928 | 0.070 |
Why?
|
| Cisplatin | 2 | 2011 | 2497 | 0.070 |
Why?
|
| Patient Participation | 1 | 2010 | 453 | 0.070 |
Why?
|
| Diphtheria Toxin | 1 | 2006 | 83 | 0.070 |
Why?
|
| Mosaicism | 1 | 2007 | 293 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2007 | 529 | 0.060 |
Why?
|
| Thyroid Hormones | 1 | 2006 | 112 | 0.060 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2005 | 43 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 5776 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 198 | 0.060 |
Why?
|
| Transcription Factors | 1 | 1999 | 5438 | 0.060 |
Why?
|
| Pyrazoles | 2 | 2020 | 1546 | 0.060 |
Why?
|
| Louisiana | 1 | 2024 | 148 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 661 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 1691 | 0.060 |
Why?
|
| Nasolacrimal Duct | 1 | 2003 | 45 | 0.060 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2003 | 51 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 242 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 1586 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2003 | 53 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2004 | 195 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2024 | 2250 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2010 | 3145 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2069 | 0.050 |
Why?
|
| Insurance | 1 | 2002 | 13 | 0.050 |
Why?
|
| Decision Making | 1 | 2010 | 1252 | 0.050 |
Why?
|
| Mycosis Fungoides | 1 | 2006 | 341 | 0.050 |
Why?
|
| Marital Status | 1 | 2002 | 92 | 0.050 |
Why?
|
| Off-Label Use | 2 | 2015 | 48 | 0.050 |
Why?
|
| Prevalence | 3 | 2019 | 3404 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 1441 | 0.050 |
Why?
|
| Benzamides | 1 | 2008 | 1879 | 0.050 |
Why?
|
| Reoperation | 5 | 2004 | 1392 | 0.050 |
Why?
|
| Medical Errors | 1 | 2004 | 210 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2011 | 12103 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2006 | 889 | 0.050 |
Why?
|
| Hyperparathyroidism | 1 | 2002 | 101 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 1012 | 0.050 |
Why?
|
| Insulinoma | 1 | 2002 | 53 | 0.050 |
Why?
|
| Health Status | 1 | 2006 | 631 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2003 | 126 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2008 | 1330 | 0.050 |
Why?
|
| Employment | 1 | 2002 | 121 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2024 | 275 | 0.050 |
Why?
|
| Income | 1 | 2002 | 235 | 0.050 |
Why?
|
| Survival | 2 | 2012 | 183 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 318 | 0.050 |
Why?
|
| Aftercare | 1 | 2003 | 252 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2002 | 143 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 1269 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 665 | 0.050 |
Why?
|
| Animals | 4 | 2021 | 61956 | 0.040 |
Why?
|
| Kinetics | 1 | 2003 | 2220 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 7895 | 0.040 |
Why?
|
| ErbB Receptors | 2 | 2007 | 2375 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 3028 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 7655 | 0.040 |
Why?
|
| North America | 1 | 2020 | 338 | 0.040 |
Why?
|
| Quality of Life | 3 | 2015 | 4761 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 1999 | 38 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2145 | 0.040 |
Why?
|
| Retinoid X Receptors | 1 | 1999 | 85 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2012 | 751 | 0.040 |
Why?
|
| Ligases | 1 | 2019 | 81 | 0.040 |
Why?
|
| Retinoids | 1 | 1999 | 149 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 896 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2022 | 902 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 4000 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2018 | 161 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 164 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 114 | 0.040 |
Why?
|
| Phenotype | 4 | 2019 | 6509 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 3108 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 318 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 442 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 919 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2011 | 1322 | 0.030 |
Why?
|
| Cell Proliferation | 3 | 2021 | 7238 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2400 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2000 | 359 | 0.030 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2016 | 25 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 360 | 0.030 |
Why?
|
| Ligands | 1 | 1999 | 1012 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 218 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 2175 | 0.030 |
Why?
|
| Haplotypes | 1 | 2019 | 910 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2000 | 672 | 0.030 |
Why?
|
| Threonine | 1 | 2016 | 163 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 1024 | 0.030 |
Why?
|
| Methionine | 1 | 2016 | 170 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 528 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2018 | 927 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2018 | 417 | 0.030 |
Why?
|
| Physical Examination | 2 | 2009 | 305 | 0.030 |
Why?
|
| Models, Econometric | 1 | 2014 | 14 | 0.030 |
Why?
|
| Smoking | 1 | 2024 | 2555 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 432 | 0.030 |
Why?
|
| Triiodothyronine | 2 | 2006 | 84 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 516 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1189 | 0.030 |
Why?
|
| Health Services | 1 | 2014 | 100 | 0.030 |
Why?
|
| Recurrence | 1 | 2002 | 4878 | 0.030 |
Why?
|
| Markov Chains | 1 | 2014 | 185 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 4147 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2016 | 589 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 506 | 0.030 |
Why?
|
| Intestinal Absorption | 1 | 1994 | 207 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 236 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 5574 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2009 | 6224 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2016 | 766 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 2617 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2000 | 1857 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 361 | 0.030 |
Why?
|
| Base Sequence | 2 | 2011 | 5437 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2014 | 202 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2014 | 149 | 0.030 |
Why?
|
| Pituitary Function Tests | 1 | 1992 | 8 | 0.030 |
Why?
|
| Bromocriptine | 1 | 1992 | 10 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 2042 | 0.030 |
Why?
|
| Reference Values | 1 | 1994 | 1133 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 99 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 1099 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 3298 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1996 | 591 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 4821 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1999 | 3216 | 0.020 |
Why?
|
| Odds Ratio | 1 | 1996 | 2311 | 0.020 |
Why?
|
| Securin | 1 | 2011 | 12 | 0.020 |
Why?
|
| Fluorine | 1 | 2011 | 22 | 0.020 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2011 | 48 | 0.020 |
Why?
|
| Consensus | 1 | 2016 | 1106 | 0.020 |
Why?
|
| Anaplasia | 1 | 2010 | 17 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2010 | 26 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 1320 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 1034 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2010 | 42 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 1430 | 0.020 |
Why?
|
| Neoplasm, Residual | 2 | 2008 | 1754 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 964 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2014 | 17061 | 0.020 |
Why?
|
| Venoms | 1 | 2010 | 25 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2359 | 0.020 |
Why?
|
| Paclitaxel | 2 | 2009 | 2101 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 188 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1235 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2012 | 3077 | 0.020 |
Why?
|
| Nerve Compression Syndromes | 1 | 2009 | 32 | 0.020 |
Why?
|
| Optic Chiasm | 1 | 2009 | 42 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 109 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 477 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 3891 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2828 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 469 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 4328 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4492 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 1571 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 4372 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 1496 | 0.020 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2007 | 50 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 749 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2009 | 139 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 886 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 529 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 967 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2009 | 300 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 1525 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 153 | 0.020 |
Why?
|
| Hospitalization | 1 | 1996 | 2167 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 822 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2007 | 163 | 0.020 |
Why?
|
| Iodide Peroxidase | 1 | 2006 | 25 | 0.020 |
Why?
|
| Whole-Body Counting | 1 | 2006 | 25 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 155 | 0.020 |
Why?
|
| Carboplatin | 1 | 2009 | 880 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 1207 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 590 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 5162 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2008 | 434 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 198 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 600 | 0.020 |
Why?
|
| Thyroid Diseases | 1 | 2006 | 85 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5923 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2315 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3584 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 2196 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2004 | 94 | 0.020 |
Why?
|
| International Cooperation | 1 | 2006 | 325 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3597 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2002 | 5257 | 0.010 |
Why?
|
| Addison Disease | 1 | 2004 | 8 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 1286 | 0.010 |
Why?
|
| Peptides | 1 | 2010 | 1504 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2009 | 1741 | 0.010 |
Why?
|
| Triglycerides | 1 | 2006 | 611 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 1021 | 0.010 |
Why?
|
| Gamma Cameras | 1 | 2003 | 39 | 0.010 |
Why?
|
| Hepatitis C, Chronic | 1 | 2009 | 471 | 0.010 |
Why?
|
| Exons | 1 | 2007 | 1383 | 0.010 |
Why?
|
| Mice | 2 | 2021 | 35600 | 0.010 |
Why?
|
| Length of Stay | 1 | 1991 | 2007 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 495 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2004 | 145 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2003 | 251 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 2003 | 59 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2003 | 184 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 439 | 0.010 |
Why?
|
| Nickel | 1 | 2002 | 45 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2003 | 201 | 0.010 |
Why?
|
| Cognition | 1 | 2008 | 959 | 0.010 |
Why?
|
| Artifacts | 1 | 2005 | 536 | 0.010 |
Why?
|
| Titanium | 1 | 2002 | 62 | 0.010 |
Why?
|
| Neurofibromatosis 1 | 1 | 2004 | 159 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 2003 | 264 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2004 | 296 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2002 | 234 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 334 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 1986 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 367 | 0.010 |
Why?
|
| Mortality | 1 | 2003 | 347 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 1642 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 5231 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2004 | 632 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6685 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 3409 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 678 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 518 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 13999 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 4481 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 3484 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1991 | 2224 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 2651 | 0.010 |
Why?
|
| Pain | 1 | 2006 | 1694 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 4329 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 5759 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 1997 | 70 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 4942 | 0.010 |
Why?
|
| Obesity | 1 | 2009 | 2904 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2431 | 0.010 |
Why?
|